Microwave Ablation Versus Liver Resection for Intrahepatic Cholangiocarcinoma

Launched by CHINESE PLA GENERAL HOSPITAL · Jun 12, 2024

Keywords

ClinConnect Summary

This clinical trial is comparing two different treatments for a type of liver cancer called intrahepatic cholangiocarcinoma (iCCA). Researchers want to find out if a procedure called microwave ablation (MWA), which uses heat to destroy cancer cells, can be just as effective as traditional surgery (liver resection) for treating this disease. They will look at how long patients survive and how often the cancer comes back after either treatment. The study will also explore which patients might be best suited for microwave ablation as their first treatment option.

To participate in this trial, patients need to have a confirmed diagnosis of iCCA and be eligible for either microwave ablation or liver surgery. Key requirements include having a single tumor that is 5 centimeters or smaller, or multiple tumors that meet certain size criteria, and being at least 18 years old. Participants will receive either MWA or surgery based on their eligibility, and the researchers will follow their progress to gather important data. This study is currently recruiting participants, so if you or someone you know is affected by iCCA, it might be a good opportunity to consider.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. pathologically diagnosed iCCA based on the WHO classifications;
• • 2. curative-intent liver resection or microwave ablation;
• • 3. tumor within Milan criteria, namely single tumor ≤5cm in maximum diameter; multiple tumors ≤3 in number and each ≤3cm; no evidence of major vascular/hilar invasion, extrahepatic/lymphatic metastasis or other malignancies;
• • 4. age ≥18 years.
• Exclusion Criteria:
• • Patients not meeting any one of the inclusion criteria were excluded.